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Hepatocellular carcinoma in Australia’s 
Northern Territory: high incidence and 
poor outcome
Abstract 
Objective: To describe the epidemiology, clinical features, management and 
outcomes of hepatocellular carcinoma (HCC) in the Northern Territory over the 
past decade.
Design, setting and patients: An NT-wide epidemiology study covering the 
period 1991–2010 and a clinical cohort study including patients diagnosed during 
2000–2011. HCC diagnoses were provided by the NT Cancer Registry and cross-
checked against clinical records.
Main outcome measures: Age-adjusted incidence of HCC; management; clinical 
features; and median and 1-year survival.
Results: There were 145 incident cases of HCC in the NT during 1991–2010, 
giving an age-adjusted annual incidence of 22.7/100 000 (95% CI, 17.2–26.8) for 
Indigenous Australians and 4.0/100 000 (95% CI, 2.1–5.8) for non-Indigenous 
Australians — an incidence rate ratio of 5.9 (95% CI, 4.7–7.4). There was no 
significant change in annual age-adjusted incidence over this period. The most 
common causative factors were hepatitis B virus in Indigenous people and 
hepatitis C virus in non-Indigenous people. Most people were diagnosed late, 
only 13/80 were diagnosed by screening, and outcomes were poor, with 28/80 
overall surviving to 1 year. Outcomes were better among those managed through 
a centralised multidisciplinary service than among those who were not (adjusted 
hazard ratio for death at 1 year, 0.35 [95% CI, 0.16–0.81]).
Conclusion: HCC incidence remains high in the Indigenous people of the NT. 
More resources are needed for HCC surveillance and management programs in 
this population.
Hepatocellular carcinoma (HCC) is a devastating com-plication of chronic viral 
hepatitis. It is the fifth most common 
incident cancer in the world, and the 
second most common cause of can-
cer death.1,2 HCC is among the fastest 
growing causes of cancer incidence 
and mortality in Australia,3,4 but its 
epidemiology in northern Australia 
has not been comprehensively de-
scribed, and there are no published 
analyses from the past decade. Past 
reports of the incidence of HCC in the 
Northern Territory have shown it to 
be higher than the national level and 
6–10 times higher among Indigenous 
Australians than non-Indigenous 
Australians.5,6 However, previous 
studies have been based only on re-
gistry data and have not described 
the clinical features and management 
of HCC in the NT.
The NT has a population of about 
230 000 people, of whom 30% are 
Indigenous. Indigenous Australians 
have higher rates of chronic hepatitis 
B virus (HBV) infection than the gen-
eral Australian population. Recent NT 
studies have found seroprevalence 
estimates for hepatitis B surface anti-
gen (HBsAg) in adults of 3%–12%,7-11 
compared with 1.0% for Australia as 
a whole.12 The NT also presents chal-
lenges of remoteness and cultural and 
linguistic barriers, making HCC sur-
veillance and treatment problematic. 
A universal program of vaccinating 
infants against HBV has been in place 
in the NT since 1990, and although 
this has resulted in a falling preva-
lence of HBV infection,7 it is unclear 
if there has been any impact on the 
incidence of HCC thus far.
We aimed to determine the in-
cidence of HCC in the NT over the 
past two decades and to describe the 
clinical and demographic features, 
management and outcomes of HCC 
among patients in the Top End of the 
NT over the past decade. Since some 
patients had their management coor-
dinated through a centralised liver 
clinic, we also aimed to explore the 
effect of site of care and Indigenous 
status on management and outcomes.
Methods
The study was approved by the 
Human Research Ethics Committee 
of the NT Department of Health and 
Menzies School of Health Research. 
We conducted this study in two parts: 
an NT-wide epidemiology study, and 
a retrospective cohort study includ-
ing patients only from the Top End.
NT-wide epidemiology study
Data regarding all cases of HCC dia-
gnosed among NT residents during 
1991–2010 were supplied by the NT 
Cancer Registry, which routinely 
collects HCC notifications by three 
methods: histology reports, hospital 
discharge coding and death certifi-
cates. All cases from the NT Cancer 
Registry were cross-checked against 
hospital records to confirm the dia-
gnosis. The diagnosis of HCC was 
defined according to the criteria pro-
posed by the American Association 
for the Study of Liver Diseases.13 
These criteria rely primarily on im-
aging findings; specifically, tumour 
size and appearance, and contrast 
enhancement characteristics.
Population denominator data were 
derived from the Australian Bureau 
of Statistics and the NT Government’s 
Health Gains Planning Branch.14 Age-
standardised incidence was calcu-
lated using the direct method, with 
5-year age brackets and the year 2001 
Australian standard population.15 
The estimated resident population 
(ERP) for the midpoint of each time 
period used in the analysis was used 
as the denominator when calculat-
ing rates (eg, the 2000 ERP for the 
period 1991–2010, the 1993 ERP for 
1991–1995).
Clinical retrospective cohort study
Detailed clinical data were collected 
on all patients who were resident in 
the Top End of the NT and were dia-
gnosed with HCC from 1 January 2000 
to 30 June 2011. This part of the study 
was restricted to the Top End (Darwin 
urban, Darwin rural, East Arnhem 
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and Katherine administrative re-
gions), as it is the referral base for the 
Royal Darwin Hospital (RDH), where 
we had access to medical records and 
hospital databases. The patients were 
identified by three overlapping meth-
ods: a prospective register kept by 
RDH liver clinic (2007–2011), hospi-
tal discharge coding (International 
Classification of Diseases, 10th revi-
sion, codes C22.0 and C22.9) and the 
NT Cancer Registry. For each patient, 
clinical and demographic data were 
collected from paper medical records 
and hospital pathology and radiology 
databases. Mortality data were col-
lected from the NT Government’s cli-
ent master index, which has recorded 
all deaths of NT residents occurring 
in the NT since 1995.
In 2006, a public liver clinic began 
operating at RDH, coordinating the 
diagnosis and management of HCC 
patients in the Top End using multi-
disciplinary input from Flinders 
Medical Centre in Adelaide. Before 
this, HCC patients were cared for by 
general surgery, oncology, general 
medicine or a private liver clinic. Even 
after 2006, not all HCC patients were 
managed through the RDH liver clin-
ic. Hence, for the purposes of analysis 
of management and outcomes, we 
divided the study a priori into two 
periods (2000–2005 and 2006–2011), 
and within the second period divided 
patients into those managed through 
the RDH liver clinic and those man-
aged by other medical practitioners. 
There is no coordinated program of 
HCC surveillance in the NT, but pa-
tients referred to the RDH liver clinic 
are offered HCC surveillance com-
prising a 6-monthly ultrasound scan 
and test for serum alpha-fetoprotein 
(AFP) level if they have cirrhosis or if 
they are high-risk and non-cirrhotic, 
as per international guidelines.13
Data management and statistical 
methods
Clinical data were collected on pa-
per case-record forms by a trained 
data collector, and all forms were 
checked by a liver clinic specialist 
before data entry. Data were entered 
into an Access database (Version 
12, Microsoft) and were analysed 
using Stata version 11 (StataCorp). 
Normally distributed continuous 
variables were described using 
mean and standard deviation, and 
were compared using the Student t 
test. Non-normally distributed con-
tinuous variables were described us-
ing median and interquartile range 
(IQR) and compared using the Mann–
Whitney U test. The χ  2 or Fisher ex-
act tests were used when comparing 
categorical data between two groups. 
Incidence rates were compared by 
5-year blocks and Indigenous status 
using Poisson regression. Kaplan–
Meier survival curves were compared 
using the log-rank test. A two-sided P 
of less than 0.05 was considered sta-
tistically significant. Among patients 
with chronic HBV infection, individ-
ual annual risk of HCC was estimated 
by dividing the age-specific crude 
incidence rate by the seroprevalence 
of HBsAg and multiplying the result 
by the proportion of HCC attribut-
able to HBV in the whole cohort. Cox 
proportional hazards models exam-
ining the first 12 months of follow-up 
were used for multivariate models of 
survival, with all-cause mortality as 
the outcome.
Results
Incidence of HCC in the NT, 1991–
2010
There were 145 incident cases of HCC 
in the NT over this 20-year period 
(Appendix 1; online at mja.com.
au), giving an age-adjusted annual 
incidence of 22.7/100 000 (95% CI, 
17.2–26.8 per 100 000) for Indigenous 
Australians and 4.0/100 000 (95% CI, 
2.1–5.8 per 100 000) for non-Indigen-
ous Australians — an incidence rate 
ratio of 5.9 (95% CI, 4.7–7.4). Appendix 
2 (online at mja.com.au) shows the 
age-adjusted incidence for 2006–2010 
compared with rates for comparable 
periods for Australia as a whole and 
other countries.
Crude incidence rates were steady 
over the first 15 years, but rose signifi-
cantly in the last 5 years of the study 
period, being 3.3/100 000/year for the 
period 1991–1995, 2.7 for 1996–2000, 
3.1 for 2001–2005 and 5.5 for 2006–
2010 (crude incident rate ratio for 
the last 5 years compared with the 
first 5 years, 1.66 [95% CI, 1.06–2.51]). 
However, the annual age-adjusted in-
cidence did not significantly increase 
over the study period (10.4, 6.1, 5.1 
and 7.8/100 000, respectively, for the 
four 5-year blocks as above).
The incidence was lowest among 
patients aged under 40 years and in-
creased sharply among those aged 
over 50 years, to a greater extent for 
Indigenous people than non-Indigen-
ous people (Box 1). Assuming that 
the seroprevalence of chronic HBV 
in Indigenous people over 40 years 
is 8%8-10 and that 60% of HCC is at-
tributable to HBV, we estimated the 
individual annual risk of HCC in 
HBV-infected Indigenous people to 
be 0.05% for ages 40–49 years, 0.34% 
for ages 50–59 years, 0.83% for ages 
60–69 years and 0.86% for ages 70–79 
years.
Demographic and clinical features 
of HCC in the Top End, 2000–2011
There were 80 new diagnoses of HCC 
in the Top End during 2000–2011, of 
which 37 were in Indigenous people, 
and 64 were in males (Box 2). Most pa-
tients were diagnosed with advanced 
disease; 13 were detected by screen-
ing and 21 were candidates for liver 
transplantation based on tumour 
size and number (Milan criteria16). 
The most commonly identified aeti-
ological factors were chronic HBV 
infection among Indigenous people 
(current infection in 15/37, and cur-
rent or past infection in 23/37) and 
HCV infection among non-Indigen-
ous people (21/43) (Box 2).
1  Annual incidence of hepatocellular carcinoma in the Top 
End, Northern Territory, by age group and Indigenous 
status, 2001–2010*
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Management and outcomes
Just over half the patients (42) were 
managed with palliative treatment 
only. Of the remaining 38, 12 patients 
underwent surgical resection, 10 were 
treated with oral sorafenib, eight had 
transarterial chemoembolisation, 
seven had radiofrequency ablation 
and three underwent liver transplan-
tation (some patients had more than 
one type of therapy). All patients who 
were candidates for curative or local 
ablation therapies were referred to 
Flinders Medical Centre in Adelaide.
The median time from diagnosis 
to death was 139 days overall. The 
median for Indigenous people (64 
days) was lower than that for non-
Indigenous people (172 days); the dif-
ference, although large, did not reach 
statistical significance (P = 0.07; Box 3, 
A). Although more patients were dia-
gnosed at a potentially curable stage 
during the second half of this study, 
outcomes did not significantly im-
prove (Box 4); however, within the 
second period, those managed by the 
liver clinic had better outcomes than 
those who were not (17/26 v 6/30 alive 
at 1 year; P = 0.001; hazard ratio for 
death, 0.32 [95% CI, 0.15–0.70]; Box 4 
and Box 3, B). Among the small group 
of patients diagnosed at a potentially 
curable stage (ie, within the Milan 
criteria), curative treatment was re-
ceived by 6/12 patients in the RDH 
liver clinic group and 0/7 patients 
managed in other settings (P = 0.02).
In a multivariate model controlling 
for age, sex, Indigenous status and 
cirrhosis, management through the 
RDH liver clinic remained the only 
significant predictor of survival at 1 
year (adjusted hazard ratio, 0.35 [95% 
CI, 0.16–0.81]).
Discussion
Despite the rising incidence of HCC 
in Australia as a whole, it remains 
about six times more common among 
Indigenous people than non-Indigen-
ous people in the NT. The incidence 
rate for Indigenous people is similar 
to the relatively high population-wide 
rate in China. Hepatitis B infection is 
the most important aetiological factor 
among Indigenous people, and there 
was no decrease in HCC incidence or 
in the proportion of HCC attribut-
able to HBV over the 20-year period 
after the introduction of universal 
infant HBV vaccination in the NT. 
We also found an independent as-
sociation between management of 
HCC through a centralised service, 
in close liaison with a referral centre 
and coordinated care, and improved 
outcomes that were not explained by 
differences in the period, patient de-
mographics or comorbidities.
Although the RDH is geographi-
cally isolated and is not a liver trans-
plant centre, the outcomes we report 
are similar to those from comparable 
urban health care systems, although 
they are inferior to those from highly 
selected case series in quaternary re-
ferral centres (Appendix 3; online at 
mja.com.au).
International guidelines recom-
mend 6-monthly surveillance for 
HCC17,18 using liver ultrasound in se-
lected high-risk people, and this has 
been shown to improve outcomes,19 
and to be cost-effective if the indi-
vidual risk of HCC exceeds 0.2% per 
year.13 However, there are no specif-
ic recommendations for screening 
Indigenous Australians with HBV 
infection. Our study shows that the 
incidence of HCC is particularly high 
among Indigenous people once they 
pass the age of 50 years. The esti-
mated individual annual risk, which 
rose from 0.34% for 50–59-year-olds 
to 0.86% for 70–79-year-olds, justi-
fies a call for HCC surveillance in all 
Indigenous Australians with HBV 
infection from the age of 50 years.
The improved outcomes in patients 
managed through the RDH liver clin-
ic may be partly attributable to earlier 
diagnosis and, thus, less advanced 
disease. However, even within the 
small group of patients diagnosed 
at a potentially curable stage, more 
patients received curative treatment 
in the RDH liver clinic group.
That there has as yet been no ob-
servable effect of the HBV vaccination 
program on HCC incidence does not 
imply that it is ineffective, but rather, 
that it has only recently been intro-
duced, since most people diagnosed 
with HCC are over 50 years of age. 
HCC incidence in China and Alaska, 
where vaccination programs have 
been in place for longer, has already 
started to decrease.20,21 Since there is a 
large pool of people born before 1990 
who have HBV infection, and a sig-
nificant proportion of HCC is caused 
by factors other than HBV, HCC will 
continue to be an important public 
health problem in the NT for decades.
2  Clinical and demographic features of patients in the Top End, Northern Territory, who were diagnosed 
with hepatocellular carcinoma, 2000–2011
All Indigenous Non-Indigenous P*
Total no. 80 37 43
Age at diagnosis, years (median [IQR]) 60.5 (53.4–66.4) 63.9 (52.9–68.6) 57.9 (54.0–64.5) 0.35
Male 64 23 41 < 0.001
Remote dwelling 29 22 7 < 0.001
Born overseas 19 0 19 —
Symptomatic presentation 52 28 24 0.14
HCC detected by screening 13 5 8 0.45
Within transplant criteria† 21 7 14 0.17
Alpha-fetoprotein > 15 IU/mL at diagnosis 42/74 18/36 24/38 0.25
HBV serology positive‡§ 38 23 15 0.05
HBsAg positive§ 22 15 7 0.02
HCV antibody positive§ 22 1 21 < 0.001
Cirrhosis 58 21 37 0.002
Alcoholic cirrhosis§ 36 13 23 0.88
Tumour number at diagnosis (median [IQR]) 2 (1–4) 2 (1–4) 2 (1–4) 0.72
Maximum tumour diameter at diagnosis, cm 
(median [IQR])
6.2 (4.2–8.1) 8.0 (5.0–11) 6.0 (3.7–7.0) 0.002
HBsAg = hepatitis B surface antigen. HBV = hepatitis B virus. HCC = hepatocellular carcinoma. HCV = hepatitis C virus. 
IQR = interquartile range. * Comparing Indigenous and non-Indigenous groups. † Milan criteria determining suitability for cure by 
liver transplantation.16 ‡ Includes both core antibody and surface antigen (ie, past or present infection). § Potential aetiological 
factors (alcohol, HBV and HCV) are not mutually exclusive. 
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Ultrasound scanning is not avail-
able in most remote NT communit-
ies. Since about 60% of Indigenous 
patients in this cohort came from 
remote communities, any HCC 
surveillance program must include 
strategies to overcome this barrier. 
Although there are many compet-
ing priorities in Indigenous health 
care in the NT, we believe the high 
incidence of and mortality from HCC 
justify the consideration of an appro-
priately resourced surveillance pro-
gram including outreach sono graphy 
ser vices. HBV case finding and an-
tiviral treatment have been shown 
to be cost-effective for preventing 
HCC in high-risk populations,22 so 
resources to reduce the impact of 
HCC should be broadly directed at 
HBV screening and treatment as well 
as HCC surveillance.
In conclusion, both incidence of 
and mortality from HCC remain un-
acceptably high among Indigenous 
people in the NT, but outcomes can be 
improved if tumours are dia gnosed at 
an early and treatable stage and care 
is coordinated through a centralised 
service. Furthermore, Indigenous 
people aged over 50 years should be 
added to the previously designated 
groups at higher risk of HCC for 
whom surveillance is recommended.
3  Kaplan-Meier survival curves comparing Indigenous and non-Indigenous 
patients diagnosed with hepatocellular carcinoma, 2000–2011 (A) and patients 
who did or did not receive centrally coordinated care through the liver clinic 
during 2006–2011 (B)
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4 Tumour characteristics, demographics, management and outcomes of patients with hepatocellular carcinoma according to 
period of diagnosis
All patients 
2000–2005
All patients 
2006–2011 P*
Managed by RDH liver 
clinic 2006–2011
Not managed by RDH 
liver clinic 2006–2011 P†
Total no. 24 56 26 30
Indigenous 13 24 0.35 8 16 0.09
Age at diagnosis, years 
(median [IQR])
51.5 (40.2–68.3) 58.4 (54.2–66.0) 0.90 57.0 (54.3–64.5) 61.0 (54.0–69.4) 0.17
Cirrhosis 15 43 0.15 23 20 0.08
Diagnosed by screening 0 13 0.01 11 2 0.003
Within transplant criteria‡ 2 19 0.02 12 7 0.07
Maximum tumour diameter at 
diagnosis, cm (median [IQR])
7.0 (6.0–9.0) 6.0 (3.7–8.1) 0.47 4.75 (2.9–6.8) 7.5 (5.0–8.3) 0.06
HBV serology positive§ 9 29 0.24 13 16 0.80
HBsAg positive 5 17 0.38 8 14 0.22
HCV antibody positive 2 20 0.01 11 9 0.39
Received potentially curative 
therapy¶
7 12 0.46 9 3 0.03
Alive at 1 year 5 23 0.10 17 6 0.001
HBsAg = hepatitis B surface antigen. HBV = hepatitis B virus. HCV = hepatitis C virus. IQR = interquartile range. RDH = Royal Darwin Hospital. * P for patients 
diagnosed during the years 2000–2005 compared with 2006–2011. † P for patients whose management was coordinated through the liver clinic 
compared with those who were not, both within the period 2006–2011. ‡ Milan criteria determining suitability for cure by liver transplantation.16 § Includes 
both core antibody and surface antigen (ie, past or present infection). ¶ Potentially curative therapy includes liver transplantation, resection of the tumour 
and radiofrequency ablation of small tumours. 
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